577 related articles for article (PubMed ID: 28371155)
21. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
22. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
[TBL] [Abstract][Full Text] [Related]
23. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
26. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A; Tan B; Somayaji VR; Calle RA; Kazierad DJ
Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
[TBL] [Abstract][Full Text] [Related]
27. Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Agrawal S; Gupta Y
Diabetes Care; 2016 Nov; 39(11):e198. PubMed ID: 27926897
[No Abstract] [Full Text] [Related]
28. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
29. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
30. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).
Johansen ML; Schou M; Rossignol P; Holm MR; Rasmussen J; Brandt N; Frandsen M; Chabanova E; Dela F; Faber J; Kistorp C
Diabetes Obes Metab; 2019 Oct; 21(10):2305-2314. PubMed ID: 31183945
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes.
D'Souza NC; Aiken JA; Hoffman EG; Atherley SC; Champsi S; Aleali N; Shakeri D; El-Zahed M; Akbarian N; Nejad-Mansouri M; Bavani PZ; Liggins RL; Chan O; Riddell MC
Front Pharmacol; 2024; 15():1302015. PubMed ID: 38510652
[No Abstract] [Full Text] [Related]
32. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.
Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
J Clin Lipidol; 2024; 18(2):e261-e268. PubMed ID: 38158248
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.
Shankar SS; Daniels SJ; Robertson D; Sarv J; Sánchez J; Carter D; Jermutus L; Challis B; Sanyal AJ
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38729399
[TBL] [Abstract][Full Text] [Related]
34. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
Scheen AJ; Paquot N; Lefèbvre PJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1373-1389. PubMed ID: 29052441
[TBL] [Abstract][Full Text] [Related]
35. Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2017 Jun; 40(6):808. PubMed ID: 28420698
[No Abstract] [Full Text] [Related]
36. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Engel SS; Suryawanshi S; Stevens SR; Josse RG; Cornel JH; Jakuboniene N; Riefflin A; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
[TBL] [Abstract][Full Text] [Related]
37. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
Fanaroff AC; Roe MT; Clare RM; Lokhnygina Y; Navar AM; Giugliano RP; Wiviott SD; Tershakovec AM; Braunwald E; Blazing MA
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28923989
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study.
Yokote K; Kanada S; Matsuoka O; Sekino H; Imai K; Tabira J; Matsuoka N; Chaudhuri S; Teramoto T
Circ J; 2017 Sep; 81(10):1496-1505. PubMed ID: 28539539
[TBL] [Abstract][Full Text] [Related]
39. Psychotropics and Male Reproduction.
Drobnis EZ; Nangia AK
Adv Exp Med Biol; 2017; 1034():63-101. PubMed ID: 29256128
[TBL] [Abstract][Full Text] [Related]
40. SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Elkind-Hirsch KE; Paterson MS; Shaler D; Gutowski HC
Endocr Pract; 2018 Apr; 24(4):361-368. PubMed ID: 29561188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
